Article

Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study

Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon, CH-1011 Lausanne, Switzerland.
BMC Cancer (Impact Factor: 3.32). 02/2008; 8:86. DOI: 10.1186/1471-2407-8-86
Source: PubMed

ABSTRACT To asses the clinical profile, treatment outcome and prognostic factors in primary breast lymphoma (PBL).
Between 1970 and 2000, 84 consecutive patients with PBL were treated in 20 institutions of the Rare Cancer Network. Forty-six patients had Ann Arbor stage IE, 33 stage IIE, 1 stage IIIE, 2 stage IVE and 2 an unknown stage. Twenty-one underwent a mastectomy, 39 conservative surgery and 23 biopsy; 51 received radiotherapy (RT) with (n = 37) or without (n = 14) chemotherapy. Median RT dose was 40 Gy (range 12-55 Gy).
Ten (12%) patients progressed locally and 43 (55%) had a systemic relapse. Central nervous system (CNS) was the site of relapse in 12 (14%) cases. The 5-yr overall survival, lymphoma-specific survival, disease-free survival and local control rates were 53%, 59%, 41% and 87% respectively. In the univariate analyses, favorable prognostic factors were early stage, conservative surgery, RT administration and combined modality treatment. Multivariate analysis showed that early stage and the use of RT were favorable prognostic factors.
The outcome of PBL is fair. Local control is excellent with RT or combined modality treatment but systemic relapses, including that in the CNS, occurs frequently.

0 Followers
 · 
167 Views
  • Source
    • "Primary breast lymphoma (PBL) is a rare but distinct extranodal lymphoma subtype, comprising 0.5% of breast malignancies, around 1% of all non-Hodgkin lymphoma (NHL) and <3% of extranodal lymphomas [1] [2] [3] [4] [5] [6]. Over 98% of cases occur in women [2] [3] [4] [5] [6] [7] [8] [9] [10]; the most common histology is diffuse large B-cell lymphoma (DLBCL). The case definition proposed by Wiseman and Liao, modified by Hugh et al. requires the presence breast tissue in close proximity with lymphoma, no antecedent diagnosis of lymphoma and no extramammary disease other than ipsilateral axillary nodes [11] [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Primary breast lymphoma is a rare form of extranodal lymphoma, defined by the presence of a primary lesion within the breast with or without regional nodal involvement but no other extra-mammary sites of involvement. It comprises diverse histologic subtypes, but diffuse large B-cell lymphoma is the most common. In this review, we describe in detail the clinical features, diagnosis and staging, pathogenesis, risk factors and therapy of primary breast diffuse large B-cell lymphoma. We consider choice and number of cycles of chemotherapy, the indications for radiotherapy and discuss the need for central nervous system prophylaxis. We also provide a brief overview of the less commonly encountered histologic subtypes including marginal zone, follicular, Burkitt and breast implant associated anaplastic large cell lymphoma. We conclude with a suggested treatment approach and potential areas of future research.
    Cancer Treatment Reviews 09/2014; 40(8). DOI:10.1016/j.ctrv.2014.05.010 · 6.47 Impact Factor
  • Source
    • "Cette inquiétude a même suscité une mise en garde de la part de la Food and Drug Administration (FDA) en janvier 2011 [1]. Les lymphomes primitifs du sein sont des tumeurs rares, représentant de 0,04 % à 0,5 % [2] [3] des tumeurs du sein et la localisation mammaire des lymphomes non hodgkiniens (LNH) ne représente que 0,3 % à 0,7 % des LNH et 1,7 % à 2,2 % des localisations extraganglionnaires [2] [3]. De plus, les LNH de type T affectant le sein sont encore plus rares, 95 % des lymphomes primitifs mammaires étant de type B [4] [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is a new concern about a possible association between anaplastic large cell lymphoma (ALCL) and breast implants. The purpose of this review was to identify and analyze all reported cases of ALCL occurring in patients with breast implants. Therefore, we reviewed all articles published concerning this subject between 1991 and 2011. We found 41 cases of ALCL. The mean age of the patients was 51 years old with an average of 108 months between the implantation and the diagnosis. Over 60 % of the reported cases were aesthetic augmentations. However, none of the published study managed to highlight a correlation between the prosthesis and this lymphoma. Therefore, we believe that for the moment, we can reassure our patients, but we must be aware of this association if a late seroma or a tumefaction occur on prosthesis. The surgical management seems to be essential for the diagnosis and the treatment, especially by the negative ALK and CD 30 expression of this lymphoma.
    Annales de Chirurgie Plastique Esthétique 02/2012; 57(1):1–8. DOI:10.1016/j.anplas.2011.11.007 · 0.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Extranodal non-Hodgkin lymphoma of the breast is a rare disease. We present a case of primary breast lymphoma with atypical clinical manifestations that looked like acute mastitis. A 46-year-old woman had noted a painful swelling in the right breast for 2 months. The mass had an inflammatory appearance and acute mastitis was the clinical impression. She underwent a core biopsy of the mass, and pathology showed inflammatory changes. The inflammatory mass regressed and recurred during hospitalization, and further incision with debridement was done. The histological findings were consistent with diffuse large B cell lymphoma. Systemic examination found stage IIE disease. She received chemotherapy and local radiation is planned.
    Tumori 01/2011; 97(2):233-5. DOI:10.1700/667.7790 · 1.09 Impact Factor
Show more